Abstract
Sunitinib demonstrating efficacy in pancreatic islet cell carcinomas will pave the way for further trials in other neuroendocrine tumor types such as carcinoid, poorly differentiated neuroendocrine disease, and several other endocrine tumors that are dependent on VEGF/VEGFR for angiogenesis. In addition, other drugs with distinct mechanisms of action, such as mTOR inhibitors, currently investigated in phase III trials, may also supply novel options in those diseases to control tumor growth and metastasis.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biomarkers, Tumor
-
Carcinoid Tumor / drug therapy
-
Cell Line, Tumor
-
Clinical Trials as Topic
-
Dose-Response Relationship, Drug
-
Drug Resistance, Neoplasm
-
ErbB Receptors / therapeutic use
-
Humans
-
Indoles / therapeutic use*
-
Kidney Neoplasms / drug therapy
-
Lung Neoplasms / drug therapy*
-
Melphalan / therapeutic use
-
Neovascularization, Pathologic / prevention & control*
-
Neuroendocrine Tumors / drug therapy*
-
Pancreatic Neoplasms / drug therapy
-
Procarbazine / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins c-kit
-
Pyrroles / therapeutic use*
-
Sunitinib
-
Vinblastine / therapeutic use
-
Xenograft Model Antitumor Assays
Substances
-
Angiogenesis Inhibitors
-
Biomarkers, Tumor
-
Indoles
-
Protein Kinase Inhibitors
-
Pyrroles
-
Procarbazine
-
Vinblastine
-
ErbB Receptors
-
Proto-Oncogene Proteins c-kit
-
Melphalan
-
Sunitinib